Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Steven Fincher

Internal Medicine Searcy, AR Medical Doctor

NPI 1689637860 CMS profile 30536

2900 Hawkins Dr, Searcy, AR 72143

Open in the dashboard

General payments

$2,843

189 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Steven Fincher of Searcy, AR is reported in the CMS Open Payments database as having received $2,843 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $14 1
2023 General $17 1
2022 General $171 10
2021 General $863 57
2020 General $764 48
2019 General $1,014 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Fincher
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Steven Fincher were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Steven Fincher Internal Medicine median Middle half National median
2019 $1,014 $159 $48–$570 $163
2020 $764 $119 $33–$402 $114
2021 $863 $135 $37–$521 $132
2022 $171 $141 $42–$496 $149
2023 $17 $149 $45–$519 $160
2024 $14 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Amgen Inc. $730 44 payments
  2. Novo Nordisk Inc $536 36 payments
  3. Sanofi-Aventis U.S. LLC $479 35 payments
  4. Pfizer Inc. $337 24 payments
  5. GlaxoSmithKline, LLC. $162 12 payments
  6. AstraZeneca Pharmaceuticals LP $154 10 payments
  7. Abbott Laboratories $83 5 payments
  8. Nestle HealthCare Nutrition Inc. $74 4 payments
  9. E.R. Squibb & Sons, L.L.C. $64 5 payments
  10. Mylan Specialty L.P. $62 4 payments
  11. Other $162 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,843 189 payments
Products named General payments · program years 2019–2024
  1. Prolia $463 26 payments
  2. Ozempic $421 29 payments
  3. EVENITY $415 23 payments
  4. RYBELSUS $252 17 payments
  5. Repatha $230 15 payments
  6. AIMOVIG $211 15 payments
  7. Tresiba $193 12 payments
  8. TRELEGY ELLIPTA $162 12 payments
  9. SOLIQUA 100/33 $143 10 payments
  10. FARXIGA $142 9 payments
  11. Other $1,626 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record